ECOG-ACRIN Cancer Research Group

ECOG-ACRIN Cancer Research Group Biomarker-driven research involving adults who have or are at risk of developing cancer

EA7222, led by Dr. Seth Pollack of , is a randomized phase 3 trial of doxorubicin alone or in combination with pembrol...
06/03/2026

EA7222, led by Dr. Seth Pollack of , is a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab for patients with advanced soft tissue sarcoma and related poorly differentiated sarcomas that are unresectable. https://bit.ly/EA7222

Do you have early-stage and are age 75 or older? If so, you may be eligible to participate in this study of a potentia...
06/03/2026

Do you have early-stage and are age 75 or older? If so, you may be eligible to participate in this study of a potential new treatment approach. More info: https://bit.ly/ea6244-study

Do you have advanced has become worse following treatment, or advanced cancer for which no standard treatment exists? ...
06/03/2026

Do you have advanced has become worse following treatment, or advanced cancer for which no standard treatment exists? If so, you may be able to join the study. Learn more: http://bit.ly/ComboMATCH

Clinical trial EA4231, led by Christopher Melani, MD of National Cancer Institute, is testing the effectiveness of a com...
06/02/2026

Clinical trial EA4231, led by Christopher Melani, MD of National Cancer Institute, is testing the effectiveness of a combination targeted therapy for patients with aggressive B-cell that has recurred or is resistant to treatment. For more: https://bit.ly/EA4231

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy ...
06/02/2026

Urothelial cancer is the most common type of bladder cancer. The EA8192 study is evaluating durvalumab and chemotherapy for patients with high grade upper tract urothelial cancer prior to nephroureterectomy. https://bit.ly/ea8192-trialhttps://bit.ly/ea8192-trial

Do you have that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a s...
06/02/2026

Do you have that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: https://bit.ly/ea1242-study

06/02/2026

New insights from Day 4 continue to shape the landscape—including updates from ECOG-ACRIN Cancer Research Group studies in (EA5142/ALCHEMIST), and (EA6174/STAMP). Helpful podcast summary for a quick download:

Do you have advanced non-small cell and are age 70 or older? If so, you may be able to participate in this study of a ...
06/02/2026

Do you have advanced non-small cell and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://bit.ly/ea5221-achieve

In clinical trial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery al...
06/01/2026

In clinical trial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery alone for patients with high-risk retroperitoneal . More info: https://bit.ly/EA7211

Clinical trial EA1241 is evaluating tissue samples from past TAILORx & RxPONDER trial participants who experienced a rec...
06/01/2026

Clinical trial EA1241 is evaluating tissue samples from past TAILORx & RxPONDER trial participants who experienced a recurrence. This research aims to uncover why breast cancer returns after treatment. More: https://bit.ly/EA1241

Address

Philadelphia, PA

Telephone

+12157893631

Website

http://linktr.ee/ecog_acrin

Alerts

Be the first to know and let us send you an email when ECOG-ACRIN Cancer Research Group posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category